Steve Jobs’ rare form of pancreatic cancer has high survival rate

“Neuroendocrine tumors, the kind that Apple Chief Executive Officer Steve Jobs had surgically removed during the weekend, fall into a tiny category of pancreatic cancers that tend to grow very slowly and have a high survival rate, medical experts said Monday,” Ulysses Torassa reports for The San Francisco Chronicle. “Jobs’ form of the disease accounts for less than 5 percent of the 32,000 pancreatic cancer cases diagnosed each year in the United States.”

“Dr. Jeffrey Norton, a specialist in cancers of the digestive system at Stanford University Medical Center, said an estimated 80 to 90 percent of patients are still alive after 10 years, although predictions are difficult because the number of cases is so small,” Torassa reports.

Full article here.

MacDailyNews Take: Leave it to Steve to get the rare form (less than 5%) of pancreatic cancer that closely matches Mac market share. Thank God!

4 Comments

  1. I only know two kinds — the one’s there’s no getting away from and the others. By definition, there’s no cure for the former, only therapies that’ll make your remaining time terribly uncomfortable. When it comes to the “c” word, the pace of innovation is glacial.

    So Steve dodged a bullet … hooray and all that … but how many of us are getting shot at at this very moment? We need a permanent cure for these suckers for once and for all.

Leave a Reply to Less is More Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.